Past analysis identified a seasonal development in blood lead levels in children in multiple North American towns, including Washington, D.C., New York, Chicago and Milwaukee. Those known levels increase, often by more than 10 %, in July, August and September. Blood lead levels decrease during winter and spring then. The scientists attempt to check a hypothesis implicating contact with lead-contaminated dirt while children are outside and engaged in warm-weather activities – at the same time when wind, humidity and other meteorological factors increase the amounts of dust in the fresh air. Their ES&T statement describes research that strongly implicates airborne dust as the reason for the seasonal developments in blood lead amounts.Alexza Pharmaceuticals to meet up with FDA to discuss CRL regarding its NDA for AZ-004 Alexza Pharmaceuticals, Inc. announced today that the Company has planned an End-of Review ending up in the U.S. Meals and Medication Administration in December to discuss the entire Response Letter relating to the Company’s New Drug Application for AZ-004 . Related StoriesImmune submits Bertilimumab IND application to FDA for treatment of Bullous PemphigoidNovo Nordisk announces FDA approval of Tresiba for diabetes treatmentAlnylam presents positive ongoing stage 2 open-label expansion data for Patisiran and RevusiranThe Firm anticipates the FDA meeting will be a extensive review of the issues recognized by the FDA in the CRL, and Alexza’s prepared responses to those issues.S.